A Letter from CDI President Craig Strasnick: Commonwealth Diagnostics International, Inc. (CDI) today announced its commitment to assist in the continuity of care for the millions of Gastrointestinal sufferers in the United States. The healthcare delivery system is being pushed to the brink of its capacity, and these times have brought with them a significantly…
The Improved Sample Collection Method Expands Access to the Blood Test for Diagnosing DiarrheaPredominant and Mixed-Type Irritable Bowel Syndrome SALEM, MA February 1, 2020 – Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of IBSchek®, the first clinically validated biomarker blood test for…
Salem, MA – January 10, 2020 – Commonwealth Diagnostics International, Inc. (CDI) is pleased to participate in a clinical trial with the University of Michigan, one of the largest gastroenterology practices in the country and a leader in the GI community. The clinical trial, Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea (IBS-D),…
Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce its participation in the U.S. Department of Veterans Affairs’ (the VA’s) Community Care Network (CCN). The CCN is the VA’s direct link with specialized community providers, like CDI, to ensure that over 9 million enrolled Veterans receive adequate choice of and access to proper, timely, and…
Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce its participation in the Blue Cross Blue Shield of Massachusetts Network. CDI is a diagnostic laboratory located in Salem, Massachusetts that offers a variety of products, services, and technologies that aid in the diagnosis of gastrointestinal disorders such as Small Intestinal Bacterial Overgrowth (SIBO) and Irritable…
Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of IBSchek™, the first clinically validated blood test for diarrhea-predominant and mixed-type Irritable Bowel Syndrome (IBS-D, IBS-M). CDI will officially re-launch IBSchek to the gastroenterology community at Digestive Disease Week in Washington, DC in June…
Commonwealth Diagnostics International, Inc. (CDI), the leader in hydrogen and methane breath testing® for functional gastrointestinal disorders, announces its entry into the Canadian healthcare market. CDI will offer its state-of-the-art, non-invasive, functional GI diagnostic tests to the approximately five million Canadians afflicted with Irritable Bowel Syndrome (IBS)1, and millions of other patients suffering from functional…
Commonwealth Diagnostics International, Inc. (CDI), a specialized clinical diagnostics service provider, independent CLIA-certified laboratory, and medical technology company focused on the early detection and diagnosis of functional gastrointestinal disorders, announced today several strategic updates, including the official re-launch of IBSchek® – its first-in-kind blood test to rule in Irritable Bowel Syndrome – in the United States, enhancements…
Commonwealth Diagnostics International, Inc. (CDI), the global leader in hydrogen and methane breath testing for gastrointestinal disorders, announced today that it will be a title sponsor of American professional golfer, Rob Oppenheim. CDI and Oppenheim have teamed up to drive awareness around irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO), two of the leading causes of digestive distress…
Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the re-launch and integration of its customer-centric, gastroenterology-focused diagnostic testing business in the United States, including its hydrogen and methane breath testing portfolio for Small Intestinal Bacterial Overgrowth (SIBO) and carbohydrate malabsorption. This announcement comes after CDI generated…
